ASH 2022 Conference Coverage
M

ASH 2022 Long-Term Outcomes of Patients With TDT Followed Up to 8 Years Post-Treatment With Betibeglogene Autotemcel Gene Therapy and Predictors of Successful Treatment Outcomes in Phase 3 Trials

By ASH 2022 Conference Coverage FEATURING Mark Walters
By ASH 2022 Conference Coverage FEATURING Mark Walters
98 views
January 5, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

14:10
Hematology Content

An ITP Case Study in a Patient Who Is Non-responsive to Multiple Cou…

Feat. T. Gernsheimer

Featured Video

04:26
Pharmacosmos Hematology

An Introduction to an IV iron replacement therapy

Feat. H. Bahrain

Related Content

AUTOPLAY
15:39

Thalassemias: Overview of Pathophysiology and Treatment

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

K. Fertrin

1.0K views
17:38

Impact and Risks of Chronic Anemia in Thalassemia Patients

Farrukh Shah

606 views
16:09

Case-Based Discussion: Managing Non-Transfusion-Dependent Thalassemia

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Taher

1.5K views
33:17

Managing Benign Hematology Disorders

Indy Hematology Review

C. Kessler

602 views
04:54

New

Thalassemia: Overview of Pathophysiology and Risk for Malignancies

Ali Taher

192 views
05:59

Mitapivat for Thalassemia: Results From the Ph3 ENERGIZE-T Study

Stefan Eber

154 views
42:10

Highlights in Red Cell and Platelet Disorders From ASH 2023

Insights from 2023 ASH Annual Meeting

M. Blinder

298 views
33:48

Beyond Transfusion: Current Treatment Options for Managing Thalassem…

Abdulrahman Nasiri

89 views
18:15

Updates in Cellular Therapy for Sickle Cell Disease and Beta-Thalass…

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

S. Peslak

108 views
13:57

ASH 2023 Insights: "Pyruvate Kinase Activators - Targeting Red Cell …

Insights from 2023 ASH Annual Meeting

K. Kuo

130 views
08:11

ASH 2023 Insights: "A Novel Beta Globin Frameshift Mutation Causing …

Insights from 2023 ASH Annual Meeting

L. Bilston

100 views
10:22

State-of-the-Art in Managing Thalassemias

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

M. Cappellini

96 views
08:05

Mitapivat in Adults With Alpha- or Beta-Non-Transfusion-Dependent Th…

Ali Taher

36 views
12:24

The Role of Luspatercept in Transfusion-Dependent Patients With Beta…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

A. Tombak

45 views
15:43

New

Importance of PK Activation in Thalassemias

Ilham Youssry

14 views
22:07

Thalassemia Intermedia: Cases and Discussion

XV Eurasian Hematology-Oncology Congress - EHOC 2024

J. Abiyounis

18 views
19:58

Luspatercept and Blood Transfusion Management in Beta Thalassemia an…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

A. Tombak

19 views
09:49

Bu-Cy or Treosulfan-Flu-Thiotepa-Based Myeloablative Conditioning fo…

XIV Eurasian Hematology-Oncology Congress - EHOC 2023

N. Bayram

13 views
16:30

New

Supportive Management of Thalassemia With Complications: A Case Pres…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Karadaş

7 views
03:11

A Case of Thalassemia Minor Coexisting with Chronic Myeloproliferati…

XV Eurasian Hematology-Oncology Congress - EHOC 2024

E. Buyukasik

8 views